Envista Holdings Corporation

source: coverage-next-full ticker: NVST step: "01" title: Business Overview — Envista Holdings Corporation created: 2026-05-29

Step 01 — Business Overview: Envista Holdings Corporation (NVST)

Company Summary

Envista Holdings Corporation is a global dental products company operating a portfolio of more than 30 brands across dental implants, orthodontics, dental equipment, and consumables. Spun off from Danaher Corporation in September 2019, Envista was designed as a standalone dental platform inheriting Danaher's operational rigor (the "Danaher Business System") while gaining strategic independence to compete across the full dental care continuum.

Headquartered in Brea, California, Envista sells products to dental practices, dental service organizations (DSOs), dental labs, and distributors in 100+ countries. Revenue in FY2025 was $2,719.5M, making it one of the largest pure-play dental products companies in the world by revenue.

Business Segments

Segment 1: Specialty Products & Technologies (~64% of FY2025 Revenue — $1,752.8M)

Higher-growth, higher-margin segment focused on implants and orthodontics.

Dental Implants — Nobel Biocare:

• Nobel Biocare is the flagship brand and Envista's crown jewel: a 70-year-old Swiss-founded implant manufacturer with an unmatched clinical heritage, global brand equity, and a comprehensive data library
• Products: Nobel Biocare implant systems (Nobel Parallel CC, Nobel Replace, Nobel Active), abutments, regeneration products (membranes, grafting materials), guided surgery software
• Sells to premium dental practices, university dental programs, and large DSOs
• Nobel S Series: newest generation implant system, launched to accelerate premium implant adoption
• Implant Direct: Value-tier implant brand — digital-only distribution targeting cost-sensitive practices; launched to capture premium-to-value migration

Clear Aligners — Ormco / Spark:

• Ormco is a legacy orthodontics brand (metal brackets, wires, Damon System self-ligating brackets)
• Spark is Ormco's clear aligner system, the growth vehicle competing with Align Technology's Invisalign
• Spark TruGEN XR: differentiated material providing superior clarity and stain resistance vs. Invisalign
• Growing from a low base — gaining market share particularly through DSOs and GP dentists
• Spark requires continued investment in orthodontist education and customer acquisition

Segment 2: Equipment & Consumables (~36% of FY2025 Revenue — $966.7M)

Lower-growth, more stable segment focused on dental equipment and practice supplies.

Dental Equipment — KaVo / DEXIS:

• KaVo: Premium dental handpieces, dental chairs, treatment units, and sterilization equipment
• DEXIS: Digital imaging brand — intraoral sensors, cone beam CT (CBCT) scanners, 3D imaging
• DTX Studio: Envista's open digital workflow platform connecting imaging, implant planning, and guided surgery; positioned as the ecosystem hub across brands

Dental Consumables — Kerr / Other:

• Kerr: Restoratives (composites, bonding agents), endodontic files, infection control products
• Other brands: Meisinger (rotary instruments), Pelton & Crane (operatory equipment), Sola (laboratory products)

Corporate Heritage and DNA

• Danaher Connection: Envista was built from Danaher's dental business (acquired Sybron Dental 2011, Nobel Biocare 2014, Ormco pre-2019). Inherited the Danaher Business System (DBS): a continuous improvement, kaizen-based operational framework that drives lean manufacturing, quality management, and growth through acquisition integration
• Post-Spinoff Ownership: Danaher initially retained ~17% ownership post-spinoff; has since sold down to immaterial level
• IPO Structure: Envista raised ~$784M in its September 2019 IPO on NYSE

Geographic Footprint

• United States: Largest single market; DSO channel is fastest-growing go-to-market
• Europe: Germany, Switzerland, Netherlands, France, UK — strong implant and equipment presence; Nobel Biocare heritage particularly strong
• Asia-Pacific including China: ~20–25% of total revenue; China is largest APAC market and source of significant VBP-related headwind since 2023
• Rest of World: Latin America, Middle East, other emerging markets (smaller but growing)

Go-to-Market Model

• Direct sales force: Calls on dental specialists (periodontists, oral surgeons, prosthodontists) and orthodontists for premium products
• DSO sales: Dedicated DSO team targeting group practices and large dental chains; increasingly important channel as DSO consolidation accelerates
• Distribution: Third-party dental distributors (Henry Schein, Patterson, Benco) for consumables and equipment
• Digital/direct: Implant Direct operates as a digital-first, direct-to-dentist model for value implants

Key Brands Summary

Strategic Narrative (2024–2026)

Management under CEO Amir Aghdaei is executing a "portfolio-led recovery" strategy: (1) prioritize the Specialty Products segment (higher margins, faster growth) over Equipment & Consumables; (2) expand operating leverage from the depressed post-VBP/post-Spark-investment trough; (3) return capital via a now-active buyback program ($300M authorized May 2026); and (4) use DTX Studio as the digital ecosystem to deepen multi-brand relationships with DSOs and specialists.

The company targets adj. EBITDA margins of 17–20% over a multi-year horizon (vs. 13.7% in FY2025), implying ~400–600bps of margin expansion from operational leverage and mix shift as Specialty Products grows faster than Equipment & Consumables.

source: coverage-next-full ticker: NVST step: "04" title: Financial Snapshot — 5-Year P&L Summary created: 2026-05-29

Step 04 — Financial Snapshot: 5-Year P&L Summary

Annual Income Statement Summary (USD millions)

*FY2024 GAAP figures distorted by ~$1.15B goodwill impairment charge; adj. EBITDA excludes impairment

Key Observations on the P&L

Gross Margin Compression

Gross margins peaked at 57.4% in FY2022 and have compressed to 54.7% in FY2024–FY2025. The compression reflects:

1. China VBP: Nobel Biocare products subject to procurement pricing absorbed pricing cuts while fixed manufacturing costs remained; absorbed as gross margin contraction
2. Mix shift: Faster growth in lower-margin Spark (still in investment phase) and value-tier Implant Direct
3. Inflationary costs: Material and labor cost inflation in 2022–2023 passed through slower than expected in China
4. Management targets gross margin recovery toward 56–58% range through product mix improvement and manufacturing efficiencies

Operating Leverage Collapse (FY2023–FY2024) Then Partial Recovery (FY2025)

• FY2023: GAAP operating income collapsed to $32M (1.2% margin) from $319M in FY2022
  • Drivers: China VBP pricing impact ($75–100M revenue headwind), Spark investment ramp ($50–75M incremental OpEx), FX headwinds, dental market softness
• FY2024: GAAP operating income was -$1,038M, but this is almost entirely explained by a $1.15B non-cash goodwill impairment charge
  • Adjusted EBITDA (excl. impairment): ~$295M (11.7% margin) — still compressed but not negative
• FY2025: Meaningful recovery. GAAP operating income $216M (7.9% margin); Adj. EBITDA $372M (13.7% margin; +26% YoY)
  • Revenue recovery of +8.3% drove operating leverage; Spark investment less dilutive as scale grows

Non-Cash Goodwill Impairment — FY2024

• Envista took a ~$1.15B goodwill impairment in FY2024, primarily related to the Equipment & Consumables segment
• Triggered by: persistent stock price below book value, elevated interest rates raising discount rates, subdued dental equipment demand
• This was a non-cash charge that eroded book equity but did not impact cash generation
• Following the impairment, goodwill declined from $3,292M (FY2023) to $2,262M (FY2024)
• The impairment reflects real headwinds in the E&C segment but overstates the cash flow deterioration

Adjusted vs. GAAP — Why Adjusted Matters Here

Envista's GAAP figures are heavily distorted by: (1) goodwill impairments, (2) amortization of acquisition intangibles (~$150–175M/year), (3) restructuring charges, and (4) acquisition-related costs. Adjusted EBITDA and adjusted EPS are more relevant for ongoing cash-generative power analysis:

Note: The FY2023 adj. EBITDA of ~$170M reflects the real operational deterioration from VBP + Spark investment; FY2024 adjusted was ~$295M (partially recovered). FY2025 accelerated to $372M.

Earnings Per Share Trend

Adjusted EPS is the appropriate operating metric. The trajectory from $0.73 (FY2023/FY2024 trough) to $1.19 (FY2025) to $1.40E (FY2026E) represents a 91% improvement from trough to consensus estimate — a strong earnings recovery thesis.

R&D Investment

R&D spending is relatively stable at $94–114M annually (~3.7–4.2% of revenue). Key areas:

• Nobel S Series next-generation implant system
• Spark TruGEN XR aligner material and treatment planning software
• DEXIS AI imaging algorithms
• DTX Studio platform development

Profitability Path to Target

Management's long-term adj. EBITDA margin target of 17–20% (vs. 13.7% in FY2025) implies:

• ~$310–360M of additional annual EBITDA at current revenue scale
• Requires both revenue growth (mix shift to Specialty) AND cost efficiency (SG&A leverage as Spark investment matures)
• Comparable to Straumann's ~25%+ EBITDA margins (best-in-class) and Align's ~28–30% — Envista's target is achievable if Spark reaches scale